Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Will Inspect Firms That Didn’t Participate In U.S.-Canada Program

This article was originally published in The Gray Sheet

Executive Summary

Manufacturers that turned down FDA's offer to participate in its Pilot Multipurpose Audit Program (PMAP) will soon be inspected by the agency, CDRH's compliance chief says

You may also be interested in...



Good Deal? Firms Seek Details On FDA ISO Audit Report Submission Program

Device makers generally support FDA's plan for accepting voluntary international audit reports as a means for possibly delaying an FDA inspection, but firms say more details need to be spelled out before many will agree to participate

Good Deal? Firms Seek Details On FDA ISO Audit Report Submission Program

Device makers generally support FDA's plan for accepting voluntary international audit reports as a means for possibly delaying an FDA inspection, but firms say more details need to be spelled out before many will agree to participate

GMP Inspection Results Can No Longer Stay Within Borders, Says FDA

Results from manufacturing facility inspections conducted in one country will easily be shared with regulators in another in the near term, says Larry Kessler, FDA officer and chair of the Global Harmonization Task Force

Latest Headlines
See All
UsernamePublicRestriction

Register

MT026293

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel